Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
about
Mito-priming as a method to engineer Bcl-2 addiction.Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.p63 transcriptionally regulates the expression of matrix metallopeptidase 13.A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Pharmacological regulators of autophagy and their link with modulators of lupus diseaseTIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2.microRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in MedulloblastomaIntegrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinomaTIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members.Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cellsCell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.Mitochondrial apoptosis: killing cancer using the enemy within.Molecular mechanisms of drug resistance and its reversal in cancer.Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Mitochondrial targeted peptides for cancer therapy.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.Noxa and cancer therapy: Tuning up the mitochondrial death machinery in response to chemotherapy.Quantifying heterogeneity and dynamics of clonal fitness in response to perturbation.The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.Mitochondrial outer membrane permeabilization increases reactive oxygen species production and decreases mean sperm velocity but is not associated with DNA fragmentation in human sperm.Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-BSelective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphomaMild thermotolerance induced at 40 °C protects cells against hyperthermia-induced pro-apoptotic changes in Bcl-2 family proteins.Neonatal myeloid derived suppressor cells show reduced apoptosis and immunosuppressive activity upon infection with Escherichia coli.Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.Decreased mitochondrial priming determines chemoresistance of colon cancer stem cellsBcl-2 protects TK6 cells against hydroquinone-induced apoptosis through PARP-1 cytoplasm translocation and stabilizing mitochondrial membrane potential.Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.Hyperhomocysteinemia induces cardiac injury by up-regulation of p53-dependent Noxa and Bax expression through the p53 DNA methylation in ApoE(-/-) mice.Combined HAT/EZH2 modulation leads to cancer-selective cell death.
P2860
Q27334195-64CACCF9-D419-42FC-83AD-C20258E65913Q33412553-66E1EA54-457F-4EAA-A357-7F67911C5AB6Q33414307-4A3E0BF9-849B-4575-88AA-A045C7080817Q33576855-5D6668B6-67BF-437B-81AE-C8FB63C45DCFQ34294097-E900F27F-98B9-4AB3-A5B7-C2BCB15308E4Q34402759-5D9785D5-E89F-436C-A613-552D5A7B9704Q35772248-E217DD3E-A8B8-49DF-9107-62471700E5EAQ36083620-8745FC37-9D35-4134-9A66-E6AEFF120F8FQ36246425-B9AA7260-F90F-47D9-A76A-A8EBD752A81DQ36546689-47A9E514-137B-4451-B955-A609AEC5A263Q36751571-982DDED6-1238-4C26-ACC5-0E8B0ACC4DA4Q36907080-9A3FEEFC-D728-46BB-9A00-CD79CEFC25E5Q36967364-B92B5DCA-BF2B-4A7F-A3C7-566399FD8A3AQ37092954-189C6E68-11DA-452A-B2E5-750EE69A2770Q37330840-D97957C5-CEF9-4F7F-A816-CC2C00BC2181Q37412499-51EBEF70-4CCD-428C-A859-8430581BBD5AQ37725409-D2CD5700-4306-40DA-95CD-D88349DB1D62Q38151753-F2E124F6-86BE-430D-9AC4-EBC74AD4E430Q38367962-7863D927-9A89-4A70-BBB6-8F8C65B5B09EQ38372575-9A682C2B-155F-4D96-977B-A440B3B8B932Q38442515-242BFE31-A181-45AD-9C37-B06A05C7BB0AQ38542765-FCA88BD1-B084-4461-85EF-DC03F305F5FEQ38563530-41B28DA8-7DF1-4126-90ED-73321FF9BC6CQ38719564-4BD658F6-ADD8-446A-8B4D-BDAAEC0FF385Q38773607-32ECD63F-7864-42DD-A6FE-D3F892743D19Q38819019-C24C35F5-42B7-46A7-9E14-62654C861DC5Q38866647-A021B2F9-192B-4FB2-9CC7-B5635CF155ADQ38918736-C8A43E92-BA0C-40A4-BEC6-435FC7847B0AQ38925268-9A0C1AB1-D4BF-4D2A-8C66-5C39274C540EQ38936950-AD907964-99B2-40BD-AEB5-52EF5F13D6B3Q39170184-4D14AF90-1DA1-40C9-BF0E-2333BF45DB11Q39926284-74CD0E1C-B9AB-43EC-8919-07A673A7AB55Q40185074-402123F5-D148-45BB-AC5A-09D7559F9B64Q40217401-197F2C25-25AA-4504-B795-6D7CCDD5AE89Q41374031-C0314E3B-7080-40EE-807A-1EFB4BD66203Q42040567-3383074F-B401-49CC-809F-93C0D086CD73Q46316037-8835ABCD-2BBF-46BD-9E85-118C5D4B9BDAQ48316021-ADA58355-1A74-4E94-B9A2-204BA67CB703Q51040011-2FC8A487-6DFD-4142-89A4-6DD27A451637Q55093017-90B6D463-1B71-49D8-B22F-897B3F61DB43
P2860
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@en
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@nl
type
label
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@en
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@nl
prefLabel
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@en
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@nl
P2093
P2860
P356
P1476
Bcl-2 is a better ABT-737 targ ...... ted by Mcl-1, Bfl-1, or Bcl-B.
@en
P2093
B van de Kooij
R W Rooswinkel
P2860
P356
10.1038/CDDIS.2012.109
P577
2012-08-09T00:00:00Z